NASDAQ:FOLD
$13.25
(
-1.92%
)
Friday, 3rd Feb 2023
Amicus Therapeutics Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $11.14 | $13.62 | Friday, 3rd Feb 2023 FOLD stock ended at $13.25. This is 1.92% less than the trading day before Thursday, 2nd Feb 2023. During the day the stock fluctuated 2.62% from a day low at $13.17 to a day high of $13.52. |
| 90 days | $9.10 | $13.62 | |
| 52 weeks | $5.91 | $13.62 |
Historical Amicus Therapeutics prices
| Date | Open | High | Low | Close | Volume |
| 2023-02-03 | $13.40 | $13.52 | $13.17 | $13.25 | 1 662 444 |
| 2023-02-02 | $13.41 | $13.52 | $13.07 | $13.51 | 2 521 724 |
| 2023-02-01 | $13.02 | $13.32 | $12.79 | $13.16 | 3 019 883 |
| 2023-01-31 | $12.81 | $13.10 | $12.75 | $13.04 | 1 676 442 |
| 2023-01-30 | $12.80 | $12.89 | $12.62 | $12.75 | 1 377 394 |
| 2023-01-27 | $13.11 | $13.21 | $12.79 | $12.83 | 1 783 538 |
| 2023-01-26 | $13.23 | $13.32 | $12.96 | $13.17 | 1 912 452 |
| 2023-01-25 | $13.29 | $13.29 | $13.02 | $13.22 | 1 303 492 |
| 2023-01-24 | $13.05 | $13.44 | $12.80 | $13.39 | 1 491 854 |
| 2023-01-23 | $13.01 | $13.23 | $12.96 | $13.06 | 4 056 260 |
| 2023-01-20 | $13.18 | $13.18 | $12.76 | $13.03 | 2 898 602 |
| 2023-01-19 | $13.08 | $13.30 | $12.86 | $13.03 | 2 336 900 |
| 2023-01-18 | $12.58 | $13.62 | $12.51 | $13.10 | 4 180 700 |
| 2023-01-17 | $12.85 | $12.87 | $12.33 | $12.42 | 2 971 300 |
| 2023-01-13 | $12.75 | $13.12 | $12.48 | $12.83 | 3 490 148 |
| 2023-01-12 | $12.09 | $12.87 | $11.97 | $12.85 | 2 904 590 |
| 2023-01-11 | $11.42 | $12.02 | $11.24 | $12.02 | 2 221 200 |
| 2023-01-10 | $11.30 | $11.47 | $11.14 | $11.45 | 1 671 800 |
| 2023-01-09 | $11.68 | $11.73 | $11.24 | $11.30 | 2 039 269 |
| 2023-01-06 | $12.06 | $12.06 | $11.75 | $11.78 | 1 492 300 |
| 2023-01-05 | $11.93 | $12.00 | $11.58 | $11.86 | 1 326 666 |
| 2023-01-04 | $11.84 | $12.11 | $11.80 | $12.03 | 1 686 064 |
| 2023-01-03 | $12.24 | $12.31 | $11.81 | $11.93 | 1 380 565 |
| 2022-12-30 | $11.90 | $12.22 | $11.84 | $12.21 | 1 187 100 |
| 2022-12-29 | $11.87 | $12.24 | $11.76 | $12.09 | 2 100 808 |
| 2022-12-28 | $11.59 | $11.83 | $11.53 | $11.79 | 1 336 255 |
| 2022-12-27 | $11.67 | $11.74 | $11.51 | $11.53 | 969 335 |
| 2022-12-23 | $11.85 | $12.03 | $11.48 | $11.67 | 1 223 279 |
| 2022-12-22 | $11.90 | $12.09 | $11.71 | $11.91 | 1 564 049 |
| 2022-12-21 | $11.69 | $12.19 | $11.54 | $11.97 | 1 758 075 |
| 2022-12-20 | $11.61 | $11.93 | $11.61 | $11.72 | 1 844 890 |
| 2022-12-19 | $12.18 | $12.26 | $11.58 | $11.76 | 1 532 204 |
| 2022-12-16 | $12.01 | $12.50 | $11.92 | $12.23 | 4 668 389 |
| 2022-12-15 | $12.37 | $12.37 | $11.95 | $12.09 | 3 949 356 |
| 2022-12-14 | $12.31 | $12.52 | $12.14 | $12.45 | 1 541 740 |
| 2022-12-13 | $12.39 | $12.51 | $12.08 | $12.35 | 1 511 787 |
| 2022-12-12 | $11.63 | $12.30 | $11.56 | $12.25 | 1 489 102 |
| 2022-12-09 | $11.84 | $11.94 | $11.66 | $11.69 | 1 152 128 |
| 2022-12-08 | $12.23 | $12.29 | $11.94 | $11.97 | 1 676 415 |
| 2022-12-07 | $12.25 | $12.39 | $12.10 | $12.18 | 1 212 051 |
| 2022-12-06 | $12.28 | $12.44 | $12.18 | $12.25 | 1 245 067 |
| 2022-12-05 | $12.65 | $12.65 | $12.25 | $12.37 | 1 746 725 |
| 2022-12-02 | $12.16 | $12.72 | $12.12 | $12.70 | 2 237 022 |
| 2022-12-01 | $12.14 | $12.33 | $11.96 | $12.28 | 2 947 772 |
| 2022-11-30 | $11.61 | $12.15 | $11.47 | $12.10 | 2 634 129 |
| 2022-11-29 | $11.57 | $11.69 | $11.42 | $11.48 | 1 268 759 |
| 2022-11-28 | $11.50 | $11.69 | $11.29 | $11.53 | 1 989 056 |
| 2022-11-25 | $11.40 | $11.64 | $11.25 | $11.49 | 603 825 |
| 2022-11-23 | $11.59 | $11.74 | $11.27 | $11.43 | 1 464 680 |
| 2022-11-22 | $10.89 | $11.60 | $10.68 | $11.55 | 1 979 567 |
About Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzym... FOLD Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
